Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Enterprise Value (2020 - 2025)

Xeris Biopharma Holdings' Enterprise Value history spans 6 years, with the latest figure at -$111.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value fell 55.04% year-over-year to -$111.0 million, compared with a TTM value of -$111.0 million through Dec 2025, down 55.04%, and an annual FY2025 reading of -$111.0 million, down 55.04% over the prior year.
  • Enterprise Value for Q4 2025 was -$111.0 million at Xeris Biopharma Holdings, down from -$91.6 million in the prior quarter.
  • The five-year high for Enterprise Value was -$58.4 million in Q1 2025, with the low at -$132.1 million in Q1 2022.
  • Average Enterprise Value over 5 years is -$88.6 million, with a median of -$89.5 million recorded in 2024.
  • Year-over-year, Enterprise Value plummeted 145.43% in 2021 and then skyrocketed 40.6% in 2023.
  • Tracing XERS's Enterprise Value over 5 years: stood at -$102.4 million in 2021, then dropped by 19.07% to -$122.0 million in 2022, then skyrocketed by 40.6% to -$72.5 million in 2023, then increased by 1.15% to -$71.6 million in 2024, then plummeted by 55.04% to -$111.0 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Enterprise Value are -$111.0 million (Q4 2025), -$91.6 million (Q3 2025), and -$59.3 million (Q2 2025).